LEP and fatty liver disease: In fact, a very recent study also has demonstrated that ipragliflozin improved hepatic steatosis in high-fat-induced and leptin-deficient (ob/ob) obese irrespective of body weight reduction, and that ipragliflozin reduced the gene expression of de novo lipogenesis, while it did not change the expression of β oxidation-related genes [15].